52North Secures £4.72M for Oncology Innovations
52North, a pioneering med-tech company based in Cambridge, UK, has successfully secured £4.72M in funding dedicated to transforming urgent care pathways in the field of oncology. This significant financial injection was spearheaded by KHP Ventures and Cedars-Sinai Intellectual Property Co., showcasing a strong interest in the company’s innovative approach. Additional support came from a robust lineup of investors, including OKG Capital, Cambridge Enterprise Ventures, Cancer Research Horizons, Macmillan Cancer Support, and several prominent angel investors, such as biotech entrepreneur Jonathan Milner and former CEO of Roche Diagnostics, Roland Diggelmann. The collective backing from such diverse sources underscores the potential seen in 52North’s mission.
The funds garnered will be instrumental in propelling 52North's products closer to market readiness, particularly its flagship offering, Neutrocheck®.
Earlier this year, Neutrocheck® received breakthrough status from the UK Government as part of its pilot Innovative Devices Access Pathway, validating the product’s promise to revolutionize patient care in oncology. Founded in 2018 by a team of postgraduates from the prestigious University of Cambridge, 52North is dedicated to developing oncology-focused med-tech solutions. The company's commitment to providing low-cost products is aimed at streamlining urgent care pathways, ultimately enhancing patient safety across diverse socio-economic segments.
However, it is important to note that the innovative products currently being developed, including Neutrocheck®, are still undergoing regulatory processes and have not yet received authorization for commercial sale. This means that while the company is making strides toward improving healthcare delivery in oncology, patients and healthcare providers will need to remain patient as these groundbreaking technologies complete the necessary evaluations and gain approval. 52North’s journey reflects the broader trends in the healthcare industry, where the intersection of technology and patient-centered care continues to evolve, promising a brighter future for the landscape of medical treatment.
They've invested in 52North
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  KHP Ventures | 3 investment(s) investment(s) | 5 contacts contacts | |||
2 |  Cedars-Sinai Intellectual Property Co. | investment(s) investment(s) | more info | |||
3 |  OKG Capital | 1 investment(s) investment(s) | more info | |||
4 |  Cambridge Enterprise Ventures | 1 investment(s) investment(s) | more info | |||
5 |  Cancer Research Horizons | 2 investment(s) investment(s) | 9 contacts contacts | |||
6 |  Macmillan Cancer Support | 3 investment(s) investment(s) | more info |
Click here for a full list of 6,481+ startup investors in the UK